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It is extremely rare when HIV seropositive adult patients experience spontaneous loss of antibodies, that is, seroreversion. The
disappearance of HIV antibodies was occasionally attributed to iatrogenic intervention—serodeconversion. Such interventions
include: HAART; oral interferon; Chinese herbal remedies; and therapeutic AIDS vaccines derived from pooled blood. Oral
therapeutic, alloimmune AIDS vaccine, V-1 Immunitor (V1), was administered to 60000 HIV-positive Thai patients. The
administration of V1 resulted in serodeconversion among 23 individuals. The patient group consisted of 9 females (39%) and
14 males (61%) including two 2-year-old boys. The age range was 2–58 years with mean/median 29/29.3 years. Patients were
tested seropositive for HIV at least once before being enrolled on V1. The duration of treatment until discovery of seronegative
status ranged between 2 weeks and 15 months with average/median 7.2/8 months. Time to seronegativity was correlated with
baseline disease stage (R = 0.62; P = .002). The seronegative status was positively associated with V1-induced undetectable or low
viralload(R = 0.65; P = .0008). The odds ratio analysis comparing the outcome of our study with published surveys of diagnostic
accuracy of laboratory tests suggested that the probability of HIV antibody testing error was remote (P<. 000001). The possible
causes responsible for this unusual phenomenon are discussed.
Copyright © 2009 Orapun Metadilogkul et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The HIV seropositivity revealed by an antibody test is
indicative of virus infection. Due to a small proportion
of false-positive, false-negative, and ambiguous (indeter-
minate) ﬁndings occurring in a general population, this
test is not perfect but remains, however, the ﬁrst-line
laboratory procedure for diagnostic purposes. It is currently
accepted that antibody tests are nearly 100% sensitive and
about 99% speciﬁc [1, 2]. The frequency of false-positive
HIV serology in a low-prevalence population, for example,
military recruits from rural United States, is 1/135000 [1],
while for blood donors in Minnesota is 6/million [2]. A
survey of 5 million blood donors’ samples found that the
prevalence of false positives was 1/251000 [1]. To reduce the
chances of technical or clerical error, the antibody tests are
conﬁrmed by additional tests like ELISA, western blot, and
PCR analysis. When tests are combined, for example, ELISA
and western blot, the false-positive rate has been reported to
be as low as 1/100000 [3]. Others have indicated that even
when tests are combined, about 3% of the investigated sera
were false-positive, false-negative, or noninterpretable [4].
It is extremely unusual when symptomatic or asymp-
tomatic individuals with culture- or PCR-conﬁrmed HIV
infection do not produce virus-directed antibodies and
remain persistently negative beyond the expected window
period. A few such cases have been reported in the literature,
and most of which were due to agammaglobulinemia of
unknown immune dysfunction [5–11]. These exceptions
only reinforce the general notion that once a person is
diagnosed with HIV, he or she remains antibody-positive for
the rest of his or her life.
Newborn babies usually lose HIV antibodies acquired
fromtheirHIV-positivemothers.Theaveragetimetoserore-
version after birth is usually 12–16—maximum 18 months
[12]. However, with the exception of very few instances,2 Journal of Biomedicine and Biotechnology
these infants are not HIV-infected [13]. An adult with
conﬁrmed HIV infection seldom changes seropositive status.
Occasionally, this has been observed among individuals
who were at the terminal stage of disease [14, 15]. Cases
of spontaneous seroreversion among patients from other
categories are exceedingly rare [16–18].
In addition to cases of spontaneous loss of antibodies,
there are several reports attributing this phenomenon to
iatrogenic intervention, referred to as serodeconversion. The
earliest known report is related to administration of low-
dose oral interferon, whereby 18 out of 204 treated patients
became HIV-negative [19]. A clinical study of Chinese
herbal preparations revealed serodeconversion in eight AIDS
patients [20]. Two recent reports have shown for the ﬁrst
time that patients with acute or early HIV infection may
lose HIV antibodies as a result of highly active antiretroviral
therapy [21, 22], supporting the notion that serodeconver-
sion seldom occurs in patients on antiviral therapy [1].
Finally, both therapeutic AIDS vaccines produced from the
blood of HIV patients, that is, Nigerian Abalaka’s vaccine
and Cameroonian Anomah Ngu’s vaccine, were reported to
produce serodeconversion in several dozen AIDS patients
[23, 24].
V-1 Immunitor (V1)—the ﬁrst commercial therapeutic
AIDS vaccine—has been registered by the Thai FDA as
a food supplement and experimental drug [25]. The vac-
cine comprises heat-inactivated HIV antigens derived from
pooled blood of HIV-infected donors. Extensive preclinical
studies have shown that V1 is safe [25]. In a longitudinal
survey in 400 patients, about 85% reported improvement,
6% reported no diﬀerence, and 9% reported minor adverse
reactions, which did not last more than one week [26].
Our earlier open-label and subsequent placebo-controlled
clinical studies have shown that V1 administration increases
absolute CD4 and CD8 cell counts in both HIV-positive
andHIV-negativesubjects[27–29].Viralloadmeasurements
have shown statistically signiﬁcant trend toward decrease
[27]. Other clinical beneﬁts included the reversal of AIDS-
associated wasting and normalization of elevated liver
enzymes in HIV-positive patients coinfected with hepatitis
viruses [26]. Patients on V1 rarely develop new fungal or
bacterial infections, suggesting that V1 restores the mucosal
immuneresponsetoopportunisticinfections[26].Finally,in
a survival study, the end-stage AIDS patients had 15.8 times
longer life expectancy than those who declined V1 treatment
[30]. This single clinical endpoint is clearly more important
thansurrogateendpointssuchasviralloadandT-cellcounts.
In this study, we analyze yet another phenomenon associated
with V1 therapy, that is, an observation that some AIDS
patients who received V1 became HIV-antibody-negative.
2.MaterialsandMethods
2.1. Patients. Sixty thousand patients from Thailand with
documented history of HIV infection have received or are
currently receiving V1. In this retrospective survey, every
patient who became aware of HIV-antibody-negative status
following treatment with V1 was considered for the analysis.
Patients who did not have reliable antibody test, traceable to
Figure 1: The appearance of V-1 Immunitor (V1) therapeutic oral
AIDS vaccine.
the original issuing lab, were not included and only those
with conﬁrmed serodeconversion as compared to baseline
status were included in this survey. The physical examination
and patients’ interviews were performed at Rajavithi General
Hospital in Bangkok. Patients self-administered either one
or two V1 tablets per day. The dose for children was
twice smaller. With the exception of one patient (no. 22),
none of them received conventional antiretroviral therapy
or participated in any AIDS vaccine trials conducted in
Thailand during treatment period. Patient no. 22, a two-
year-old boy from Tanzania, was on AZT monotherapy
for a few months shortly after the birth but due to drug
intoleranceandlackofclinicalimprovementhediscontinued
treatment before starting on V1.
2.2. Vaccine. V-1 Immunitor (V1) is derived from specially
processed heat and chemically inactivated, pooled blood of
HIV-infected Thai donors. The vaccine is formulated into
an oral tablet according to a proprietary process developed
by us [25]. As pooled blood from unrelated donors was
used for vaccine manufacturing, V1 can be regarded as an
allovaccine since in addition to viral proteins it also contains
alloantigens from the blood. The vaccine is manufactured
in Thailand by Immunitor (Thailand) Co., Ltd., and is
approved by Thai Food and Drug Administration (FDA) as a
dietarysupplementandinvestigationaldrug.V-1Immunitor
is provided as 850 mg coated tablet—ten of which are sealed
in a “blister” package (Figure 1).
2.3.HIVTests. Mostofpatients’serawereexaminedbyrapid
tests for HIV antibodies (Bioline HIV1/2, Immunochemical
Lab, Thailand and Determine HIV1/2 Abbott/Dainabot,
Japan). Another approved antibody test used in Thailand
as a second-line test is ELISA or enzyme immunoassay
(EIA). These tests are also commercially available: Uni-
Form II Ag/Ab kit (Organon Technika, The Netherlands)
or HIV1/2 (Abbott Laboratories, USA). Occasionally, latex
particle agglutination test (GPA, Serodia-HIV 1/2, Fujirebio
Inc., Japan) was utilized as an alternative to ELISA. The
choice of second-line tests depended on their availability
at the testing lab and patients’ ability to pay for them. In
some cases, commercial western blot assay was conducted
in addition to antibody tests (HIV Blot 2.2, GenelabsJournal of Biomedicine and Biotechnology 3
Diagnostics, Singapore). As tests were performed in diﬀerent
labs, the QA/QC standards may vary but these variables were
beyond our control due to retrospective nature of this study.
2.4. Viral Load Measurement. Plasma viral concentrations
were measured at various independent hospitals and com-
mercial labs at patients’ own choice. As PCR tests are
expensive, very few patients were able to aﬀord such tests.
Depending on the individual lab, the commercial viral load
kits were used without any speciﬁc preference. These quanti-
tative PCR kits were either RNA PCR kit (Roche Diagnostic
Systems, Inc., Branchburg, NJ, USA) or branched DNA kit
(Bayer, Tarrytown, NJ, USA). The sensitivities of these tests
were400and50viralcopiespermL,respectively.Inaddition,
qualitative tests for HIV-1 were performed by in-house
developed PCR method according to our own published
protocol [31]. The lowest detection threshold of this test was
estimated to be not less than 100HIV copies per mL.
2.5. Statistical Analysis. Data were analyzed with StatMost
software version 2.5 (DataMost Corporation, Salt Lake City,
Utah, USA) and SISA—free online program—with courtesy
of Daan Uitenbroek. The main parametric pairwise test was
Student’s t-test. The odds ratio (OR) was estimated at 95%
Wald conﬁdence interval (CI). For assessment of correlation
between seronegative status and viral load, we have used
nonparametric Spearman’s rank-order test. The signiﬁcance
l e v e lf o ra l lt e s t sw a ss e ta tP ≤ .05.
3. Results
The patient group consisted of 9 females (39%) and 14 males
(61%) including 2 two-year-old boys. Ages ranged within 2–
58 years with a mean age of 29 years (median age = 29.5
years). The duration of V1 treatment until a patient sought
to check the antibody status ranged between 2 weeks and
15 months with an average of 7.2 months (median range =
8 months). All patients were tested for HIV seropositivity
prior to administration of V1. While most of them were
testedonlyoncebeforetreatmentinitiation,onaverage,there
were two positive tests per patient. Once patients knew the
seronegative status, many of them had tests repeated, often
at diﬀerent labs to ascertain that they were truly negative.
Thus,theaveragenumberofpost-treatmenttestswasslightly
higher (3 tests) but not statistically signiﬁcant. The results
are summarized in Table 1 which shows only those tests for
w h i c hw eh a v et r a c e a b l er e c o r d s .
At baseline, we had 13 (56.5%) patients who qualiﬁed as
having full-blown AIDS, while the remaining 2 (8.7%) and
8 (34.8%) patients had the WHO stage 2 and 3 symptoms,
respectively. Since patients with fewer symptoms were recov-
ering faster, the correlation analysis was conducted to see if
there is a relation between severity of disease and time to
serodeconversion. The results indicate that earlier you start
treatment, faster you expect to see the disappearance of HIV
antibodies (Spearman’s rank correlation, R = 0.620793; P =
.0015773).
In nine patients, viral loads were barely detectable or
undetectable after treatment, but unfortunately four of
these patients had no matching PCR tests at study entry.
Qualitative PCR tests which were conducted at the end of
study were either positive or negative. But the majority of
patients had not tested for viral load primarily due to the fact
that they could not aﬀord expensive PCR tests. Nevertheless,
from what is available to us, there is a clear impression that
serodeconversion correlates with lowered or undetectable
viral load.
Unfortunately, we do not have the complete pairwise set
of data to conﬁrm this impression by a robust parametric
test. We thus have performed nonparametric Spearman’s
rank order correlation analysis on available outcome results,
that is, nine patients: nos. 1, 2, 3, 6, 8, 9, 10, 11, and 23.
We assume that four patients—nos. 3, 6, 8, and 23—had
positive PCR results prior to the therapy. Each viral load
test, whether positive or negative, was entered as a binary
value. For example, patient no. 1 had three negative results
and a total of 3 were entered into negative results’ column;
patient no. 3 had 2 negatives and 1 positive reading, which
were entered into negative and positive results’ columns,
respectively. Patients who had no results had zeros entered
as values. In this manner, we have constructed a two-way
table to evaluate whether HIV-seronegative status had any
association with negative or positive PCR results. The results
revealed positive linear relationship with R = 0.64842 at P =
.000819. We thus conclude that serodeconversion correlates
positively with low or undetectable viral load.
Anotherreliabletestthatcouldbeperformedonavailable
data is establishment of the odds ratio, which could tell
whether our ﬁndings diﬀer from published incidence of
false-positive or false-negative results in large populations of
individuals screened for HIV antibodies. Such a statistical
test was aimed to reveal whether the observed incidence of
serodeconversion, that is, 23 individuals out of 60000, could
happenrandomlyasaresultoflaboratoryerror.Thisanalysis
was performed in 2 ×2 contingency table comparing side by
side our data with published surveys of diagnostic accuracy
of HIV tests. The results are presented in Table 2.A sc a n
be seen from Table 2, what we have observed is statistically
diﬀerent in every single case. All obtained OR values were
distant from 1—a ratio that one would expect to see if there
was no diﬀerence between our outcome and frequencies
reported by others.
4. Discussion
Due to the retrospective nature of this study, the data, espe-
cially concerning viral load, are incomplete. Nevertheless,
it is clear that obtained results are highly unusual. Why
would previously HIV-antibody-positive patients become
seronegative after treatment with V1?
The possibility that all these patients were false-positive
at the baseline is unlikely since they were symptomatic and
soughtV1treatmentbecausetheyweresuﬀeringfromAIDS-
relatedsymptoms. Thesesymptoms,thatis,low CD4counts;
weight loss; a whole range of opportunistic infections: such
as oral thrush, TB, skin lesions, persistent diarrhea, and in
one case even Kaposi’s sarcoma, were severe enough to score
them as belonging to advanced disease stage [33].4 Journal of Biomedicine and Biotechnology






































01 F3 0 4 1 3/00 14 2 5 617 <50 2
02 F3 8 2 0.5 7/01 2 2 4 <50 1
03 F3 1 3 1 8 9 / 0 1 448 2 1
04 F2 4 4 18 10/01 4 1 1
05 F2 7 3 2 9/01 2 4 1 1830
06 M2 6 3 Unknown 4/01 1 2 2 <50
07 F1 9 3 Unknown 6/01 1 1 3
08 M2 8 41 5 6 / 0 2 1 0 1 7 1
09 M3 2 3 7 4/00 15 1 10 127; 2710 <400; <50 1
10 F2 8 3 7 8/01 3 5 0 1140; 1620 1 1
11 F2 9 4 2 11/01 8 7 0 <50; <400 2 2
12 M2 4 4 24 5/02 11 3 5 43900
13 M2 8 3 1 2 2 / 0 2 914
14 M3 0 43 6 3 / 0 2 1 0 1 3
15 M4 0 4 120 3/02 10 1 1
16 M5 8 4 6 1/02 6 1 1
17 M3 2 2 0.5 12/01 0.5 1 1
18 M3 8 49 6 2 / 0 2 1 1 1 3
19 M4 3 43 2 5 / 0 2 1 1 1 4
20 M3 3 3 Unknown 5/02 3 1 1
21 M2 42 4 8 / 0 2 1 5 1 2
22 M2 4 2 4 3 / 0 2 213
23 F2 9 4 Unknown 2/02 13 1 1 <400
aTests were done at baseline before treatment initiation.
bTests were performed after treatment initiation.
cTests were done after treatment initiation, not at baseline.
dDue to high cost, some patients had qualitative PCR tests, that is, positive or negative, rather than quantitative ones—all of such tests were carried out after
treatment initiation.
Table 2: Odds ratio of observed serodeconversion rate, that is, 23 out of 60,000 patients, in comparison to published incidence rate of
erroneous HIV tests.
Report Observed Total number Odds ratio with CI at 95% Two-sided P value
[1] 1 135000 OR = 0.0193; CI = 0.002–0.1432 P<. 0000000001
[1] 1 251000 OR = 0.0104; CI = 0.001–0.077 P<. 0000000001
[2] 6 1000000 OR = 0.0157; CI = 0.0064–0.038 P<. 0000000001
[3] 1 100000 OR = 0.0261; CI = 0.004–0.1932 P = .0000000024
[4] 31 1032 OR = 78.362; CI = 45.53–134.86 P<. 0000000001
[32] 12.4 1000000 OR = 0.0324; CI = 0.0207–0.051 P<. 0000000001
One may argue that clinical symptoms were not HIV-
related and all these patients were initially false-positive
due to random incidence of such cases in general popula-
tion. This scenario, however, remains highly unlikely since,
according to the “normal” incidence of false positives in
healthy individuals, one would expect no more than 1/4
(0.25%) to 1/2 (0.5%) false-positive persons among 60000
V1-treated individuals [1]. On the contrary, in placebo-
controlled,randomized phaseIIclinicaltrialofV1 published
in2004,wehaveshownthatoneoutof29V1-treatedpatients
became HIV-negative, suggesting much higher conversion
rate [29]. The cases of true, conﬁrmed seroreversion, that
is, a seroreactive or positive sample with subsequently one
or more nonreactive samples from the same person, are
extremely rare [10–18]. In fact, most, if not all, cases of
apparent seroreversionseemto be errorsof attribution or labJournal of Biomedicine and Biotechnology 5
testing [1–4]. A survey on 2580974 army recruits identiﬁed
4911 seropositive individuals by two independent samples,
among whom only six were potential seroreverters [32].
Further review of these cases revealed that ﬁve actually were
HIV-seroreactivepatientswhohadsamplesfromnonreactive
individuals mistakenly attributed to them, while the sixth
had a testing error. Mistakes in the testing process were
identiﬁed in other 26 cases indicating the cumulative error
rate of 12.4 per 1 million individuals. In this paper, we
included only those patients who had conﬁrmed tests
traceable to the original testing lab and excluded anyone
who had indeterminate results or whose records could not
be traced. The odds ratio analysis comparing our data with
published reports of false-positive or false-negative cases in
large surveys rules out that what we have observed is a
random event due to testing error (see Table 2).
Even the two infants in our study who were born to HIV-
positive mothers are unlikely to be false-positive since they
were both symptomatic and tested repeatedly positive past
the age of 18 months, a timepoint by which the newborns
lose maternal antibodies [12, 13]. Table 1, however, shows
onlyonepositive baselinetestforeachoftheboyssinceother
tests could not be traced to original issuing labs.
Another aspect worthy of note is that patient no. 17
tested negative after 2 weeks on V1, whereas patients nos.
6a n d7b e c a m es e r o n e g a t i v ea f t e r1m o n t h .A so na v e r a g e ,
it took 7–8 months and as long as 15 months to attain
seronegative status; the two-week period appears to be very
short. Nevertheless, considering that half life of anti-p24
IgG immunoglobulin is 11–19 days, it is possible that HIV
antibodies were still present but their levels have decreased
below detection limit of standard assays [34]. This possibility
is not entirely implausible. The antibody tests of some of
the patients were ﬂuctuating from positive to negative and
back to positive during the therapy suggesting that the levels
of anti-HIV antibodies were at the borderline of detection
threshold. Furthermore, despite being seronegative, four
patients—nos. 3, 9, 10, and 11—were still showing the
presence of the virus as detected by PCR analysis. Latter
situation is reminiscent of extensively studied high-risk
seronegative (HRSN) individuals who have remained HIV-
negative despite repeated exposure to the virus. It has been
shown recently that HRSNs often carry extraordinary low
levels of HIV-1 DNA [35]. However, as opposed to our
patients, these individuals are free of disease symptoms and
are commonly known as long-term survivors.
It is not unusual to see the decline in antibodies in very
late stage of HIV disease which may be explained, in part,
by higher viral burden and reduced availability of circulating
antibodies due to antibody-antigen complex formation. In
our situation, as there is a documented decrease in viral
burden,we wouldexpect to see a surplus of antibodies rather
than their reduction. Furthermore, time to reach seronega-
tive status was not random. It was correlated with baseline
disease stage, meaning that those who are better oﬀ initially
were likely to require less time to convert than those with
advanced disease (R = 0.62; P = .002). Incidentally, all three
patients—nos. 17, 6, and 7—who converted to seronegative
status under one-month time were all in earlier disease stage.
The therapeutic vaccination was ﬁrst introduced into
clinical practice by the French researcher Daniel Zagury
as a treatment option for AIDS more than 20 years ago
[36]. Due to inherent problems associated with HAART,
this concept has become increasingly popular nowadays.
However, nearly 30 therapeutic vaccine candidates were
tested in over 60 clinical trials, but they have not produced
any evidence of clinical beneﬁt, let alone serodeconversion
[37]. The only exception are pooled blood-derived AIDS
vaccines, developed by Drs. Abalaka and Ngu, THIVAC and
VANHIVAX, respectively, which produced favorable clinical
o u t c o m e sa n dh a v ec a u s e ds e r o d e c o n v e r s i o ni ns o m eo ft h e i r
patients [23, 24]. Their results provide further support to a
possibility that what we have observed with V1 is not due to
testing or clerical error.
From the immunological point of view, this phe-
nomenon seems to be related to an observation ﬁrst made
by Stott, who reported that macaques vaccinated with
a preparation of whole killed human cells infected with
SIV were fully protected against subsequent challenge [38].
Curiously, animals immunized with a control preparation
consisting of killed human cells without SIV were also
protected. This observation appears to relate to the fact that
during the budding process through the cell membrane, SIV
as well as HIV acquires several hundred host cell molecules
[39]. Thus, the immunization with host’s proteins was equal
to or more eﬀective than immunization with viral antigens.
While the interpretation of Stott study has been contested,
several studies appear to be in agreement with this seemingly
unusual ﬁnding. For example, Lopalco et al. reported that
the enigmatic phenomenon of exposure to HIV without
seroconversion was associated with anticell auto-anti-bodies
but not with HIV-neutralizing antibodies directed against
viral antigens [40]. Sera from polytransfused, HIV-negative
individuals who often develop immune responses against
themselves, including anti-HLA antibodies, were shown to
neutralize HIV-1 [41].
The concept that AIDS is an autoimmune disease and
thus alloimmunization or in other words, immunization
with autologous cellular antigens with or without HIV anti-
gens, as a basis for immune-based therapy of HIV has been
a d v o c a t e da tl e n g t hb yu sa n do t h e r s[ 42, 43]. Several thera-
peuticapproachesbasedonthisconcepthavebeenproposed.
Daniel Zagury, who pioneered therapeutic HIV immuniza-
tion, made his original vaccine from formaldehyde-treated
leukocytes derived from the blood of seropositive patients
[36]. His vaccine has shown dramatic clinical improvements,
but unfortunately his work has not been followed. The
autologousT-cellvaccinationdevelopedbyAbulaﬁa-Lapidet
al. has shown encouraging results with over 50% (median of
70%) increase in CD4 cell counts. Their vaccine consists of
in vitro propagated, glutaraldehyde-inactivated, autologous
T cells which are injected back to HIV-positive donors [44].
Remune is another vaccine in this category; however, due to
the puriﬁcation process of virus particles from the super-
natant of cell culture, it may not possess suﬃcient quantity
of alloantigens, which may explain persistent incertitude in
clinical eﬀect [45]. Oral feeding of alloantigens, as in case of
V1, is an approach that makes sense since it induces immune6 Journal of Biomedicine and Biotechnology
tolerance—a strategy that has been shown eﬀective in ther-
apy of chronic hepatitis B and C—diseases that are caused
by autoimmune reaction against virus-carrying liver cells
rather than direct cytopathic eﬀect of hepatitis viruses [46–
48]. Israeli et al. have shown that oral feeding of hepatitis B
antigens in combination with allogeneic liver cells to patients
with chronic hepatitis leads to a dose-dependent reduction
of anti-HBV antibody titers—an observation that supports,
albeit indirectly, our ﬁndings [46]. In fact, we have shown
earlier that oral administration of V1 to normal healthy vol-
unteers does not induce systemic anti-HIV antibodies [28].
These investigations relate to the often ignored notion
of autoimmune nature of AIDS as a disease [42, 43]. If
this concept is correct, then the prevailing AIDS vaccine
strategy aimed at activating the immune response against
HIV instead of inducing immune tolerance is ﬂawed. Results
of recent trial of therapeutic AIDS vaccine in which HIV-
directed immune activation was associated with increase in
viral load further support this notion [49]. The observed
phenomenon of loss of antibodies against HIV and clin-
ical improvement can be readily explained by tolerance
induction. Due to paucity of guiding precedents relating to
serodeconversion [50–52], the present ﬁndings need to be
interpreted cautiously and additional case studies have to be
acquired and analyzed to rule out any possible error.
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